Novartis and Oxford University have begun a partnership that will attempt to use artificial intelligence to predict how patients will respond to new and existing treatments for inflammatory
Alkermes and Biogen have filed a new multiple sclerosis pill with the FDA, which they hope will treat the disease with fewer unpleasant gastrointestinal side effects than the big pharma’s o
Roche has beaten analysts’ revenue forecasts in the third quarter, after mounting sales of its older drugs in China and the success of newer drugs mitigated the impact of patent expiries.
Germany’s Merck KGaA has said it is “encouraged” by mid-stage trial results showing that its Bruton’s kinase (BTK) class drug evobrutinib reduced occurrence of central nervous system lesion
People with relapsing multiple sclerosis treated sooner with Roche’s Ocrevus saw a faster reduction in disease activity and less disability compared with those who switched from an older dr